A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark J DiNubile, MD
BioAegis Therapeutics Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cairns Hospital
Cairns, Queensland, Australia
- Box Hill Hospital
Box Hill, Victoria, Australia
- Footscray Hospital
Footscray, Victoria, Australia
- Ltd Geo Hospitals, Mtskheta Multiprofile Medical Center
Mtskheta, Georgia
- Jsc Rustavi Central Hospital
Rustavi, Georgia
- Ltd 5th Clinical Hospital
Tbilisi, Georgia
- Ltd Central University Clinic After Academic N. Kipshidze
Tbilisi, Georgia
- Ltd S. Khechinashvili University Hospital
Tbilisi, Georgia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Aug 2018
- Primary completion
- 2 Apr 2019
- Completion
- 2 Apr 2019
- Last update posted
- 27 Jan 2020
- Registered enrollment
- 33
- Registry id
- NCT03466073
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.